

## Press Release

05 July 2023 08:30:00 CEST

# Invitation to 2cureX Q2 update and Q&A session on July 12, 2023 at 20.00 (CET)

2cureX will be holding its Q2 2023 online presentation with a Q&A session on July 12, 2023 at 20.00 (CET).

2cureX Management will present status on the published goals for 2023 and additional important achievements.

From 2023, 2cureX has been arranging a Q&A session (hosted by [Stokk.io](https://stokk.io)) shortly after the end of each quarter (Q2 on July 12) and a video commentary (hosted by [Infront Direkt](https://infront.dk)) on the same day we publish the quarterly report (Q2 report on August 24). The new Q&A format allows you to submit questions both today or during the live event. You can sign up via the following link: [Q&A webcast for Q2 2023](#)). [Stokk.io](https://stokk.io) will act as moderator during the Q&A session.

The event will be livestreamed on the same link. The event is recorded and transcribed and made available for all investors afterwards on our website.

## About 2cureX

---

2cureX is a leader in cancer drug sensitivity testing and has developed the IndiTreat® (Individual Treatment) family of tests. Starting from a sample of the patient's tumor, IndiTreat® creates thousands of 3D replicas (tumoroids) and predicts the tumor response to the different available drugs, providing the physician with valuable information to make the treatment decisions.

The first three IndiTreat® tests are aimed at optimizing treatment decisions in patients with metastatic colorectal cancer (IndiTreat® Start for first line of therapy, IndiTreat® Extend and Explore for third line). Additional tests are under development to cover other stages of colorectal cancer as well as other gastrointestinal cancers.

According to several reports, the total yearly expenditure in cancer-related In Vitro Diagnostic (IVD) tests exceeds 17.5Bn USD worldwide, from which 2.5 Bn USD are tests directly related to therapy decision making, with a CAGR of 12.7%. Despite this, only one third of all cancer treatments are supported by one of these tests. IndiTreat® aims at filling this gap and making Precision Oncology available to all cancer patients.

The company is listed on Nasdaq First North Growth Market in Stockholm (symbol: "2CUREX"). For more information about 2cureX visit [www.2cureX.com](http://www.2cureX.com)

Certified Adviser: Redeye AB

## Attachments

---

[Invitation to 2cureX Q2 update and Q&A session on July 12, 2023 at 20.00 \(CET\)](#)